Drug Profile
Minocycline intravenous - Melinta Therapeutics
Alternative Names: Minocin; Minocin IV; Minocin® for Injection; Minocycline hydrochloride - The Medicines Company; RPX 602Latest Information Update: 06 Oct 2023
Price :
$50
*
At a glance
- Originator Rempex Pharmaceuticals
- Developer Rempex Pharmaceuticals; The Medicines Company
- Class Amides; Anti-inflammatories; Antiacnes; Antibacterials; Dimethylamines; Eye disorder therapies; Neuroprotectants; Skin disorder therapies; Small molecules; Tetracyclines
- Mechanism of Action Glial cell inhibitors; Interleukin 1 alpha inhibitors; Interleukin-6 modulators; Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Gram-negative infections; Gram-positive infections
Most Recent Events
- 19 Sep 2023 Rempex Pharmaceuticals withdrew a phase I trial prior to enrolment in Healthy adult volunteers in Austria (IV) due to sponsor decision (NCT03291158)
- 28 Jun 2020 No recent reports of development identified for phase-I development in Gram-negative-infections(In volunteers) in Germany (IV, Injection)
- 28 Jun 2020 No recent reports of development identified for phase-I development in Gram-positive-infections(In volunteers) in Germany (IV, Injection)